SMS Lifesciences India Ltd. (IN:HALEOSLABS)
:HALEOSLABS
Want to see IN:HALEOSLABS full AI Analyst Report?
Top Page
SMS Lifesciences India Ltd.
(HALEOSLABS)
Select Model
Select Model
Rating:69Neutral
Price Target:
₹1,368.00
▲(23.80% Upside)
Action:ReiteratedDate:11/22/25
SMS Lifesciences India Ltd. shows strong financial performance and technical momentum, which are the primary drivers of its stock score. However, the high P/E ratio and low dividend yield suggest potential overvaluation, which slightly tempers the overall score.
Positive Factors
High Revenue Growth
Sustained ~62.6% revenue growth shows durable demand for SMS Lifesciences' APIs across domestic and export channels. Higher top-line traction strengthens scale economics, supports reinvestment in capacity, and increases resilience to single-product shocks over the medium term.
Negative Factors
Cash Flow Volatility
Despite recent free cash flow improvement, documented historical inconsistencies imply operational cash conversion can fluctuate. Variable cash flows can constrain scheduled capex, delay customer qualification projects, and limit steady deleveraging or dividend policies over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
High Revenue Growth
Sustained ~62.6% revenue growth shows durable demand for SMS Lifesciences' APIs across domestic and export channels. Higher top-line traction strengthens scale economics, supports reinvestment in capacity, and increases resilience to single-product shocks over the medium term.
Read all positive factors
SMS Lifesciences India Ltd. (HALEOSLABS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹4.46B
Dividend Yield0.12%
Average Volume (3M)154.00
Price to Earnings (P/E)14.0
Beta (1Y)0.78
Revenue Growth0.63%
EPS Growth-13.85%
CountryIN
Employees592
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)21.89
Shares Outstanding3,023,287
10 Day Avg. Volume53
30 Day Avg. Volume154
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)2.00
Price to Sales (P/S)1.17
P/FCF Ratio21.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SMS Lifesciences India Ltd. Business Overview & Revenue Model
Company Description
Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, ...
How the Company Makes Money
SMSLIFE makes money mainly by producing and selling APIs and pharma intermediates to customers in the pharmaceutical industry (e.g., finished-dosage formulators and other drug manufacturers). Revenue is generated from: (1) Domestic sales: supplyin...
SMS Lifesciences India Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
68
Positive
Cash Flow
65
Positive
| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.47B | 3.37B | 3.00B | 3.13B | 3.47B | 2.65B |
| Gross Profit | 893.12M | 1.17B | 907.68M | 845.45M | 875.42M | 408.72M |
| EBITDA | 363.12M | 496.44M | 347.37M | 338.06M | 484.37M | 319.58M |
| Net Income | 145.41M | 201.09M | 90.93M | 114.63M | 253.22M | 135.57M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 3.90B | 3.91B | 3.95B | 3.57B | 3.05B |
| Cash, Cash Equivalents and Short-Term Investments | 11.92M | 15.08M | 14.93M | 36.10M | 33.56M | 110.64M |
| Total Debt | 0.00 | 864.09M | 1.01B | 1.00B | 795.98M | 651.63M |
| Total Liabilities | -2.03B | 1.78B | 1.98B | 2.07B | 1.92B | 1.76B |
| Stockholders Equity | 2.03B | 1.97B | 1.77B | 1.69B | 1.52B | 1.29B |
Cash Flow | ||||||
| Free Cash Flow | 262.34M | 187.06M | 34.38M | -338.56M | -623.94M | -25.15M |
| Operating Cash Flow | 457.63M | 340.55M | 243.06M | 146.95M | -112.41M | 330.42M |
| Investing Cash Flow | -192.05M | -149.98M | -184.50M | -312.92M | -71.43M | -266.22M |
| Financing Cash Flow | -262.87M | -191.24M | -65.64M | 168.88M | 108.33M | -310.00K |
SMS Lifesciences India Ltd. Technical Analysis
Positive
1105.00
Price Trends
1292.65
Positive
1303.66
Negative
1235.20
Positive
Market Momentum
-3.44
Negative
54.79
Neutral
49.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:HALEOSLABS, the sentiment is Positive. The current price of 1105 is below the 20-day moving average (MA) of 1265.09, below the 50-day MA of 1292.65, and below the 200-day MA of 1235.20, indicating a bullish trend. The MACD of -3.44 indicates Negative momentum. The RSI at 54.79 is Neutral, neither overbought nor oversold. The STOCH value of 49.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:HALEOSLABS.
SMS Lifesciences India Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ₹37.89B | 29.96 | ― | 0.13% | 14.96% | 27.42% | |
69 Neutral | ₹4.46B | 13.96 | ― | 0.12% | 0.63% | -13.85% | |
64 Neutral | ₹3.53B | 36.55 | ― | ― | 26.44% | 31.04% | |
59 Neutral | ₹2.16B | -338,564.26 | ― | ― | 0.76% | -116.54% | |
57 Neutral | ₹2.53B | 20.62 | ― | ― | 51.01% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | ₹1.66B | 10.71 | ― | ― | 15.44% | ― |
* Healthcare Sector Average
IN:HALEOSLABS
SMS Lifesciences India Ltd.
1,474.90
125.74
9.32%
IN:BROOKS
Brooks Laboratories Limited
56.48
-78.32
-58.10%
IN:LYKALABS
Lyka Labs Limited
60.49
-49.66
-45.08%
IN:MEDICO
Medico Remedies Ltd.
42.50
-12.54
-22.78%
IN:NURECA
Nureca Ltd.
265.35
36.55
15.97%
IN:SMSPHARMA
SMS Pharmaceuticals Limited
404.55
165.33
69.11%
SMS Lifesciences India Ltd. Corporate Events
Haleos Labs Publishes Postal Ballot Notice, Opens SEBI-Compliant Special Window
Mar 31, 2026
Haleos Labs Limited has notified the stock exchanges that it has published newspaper advertisements on 31 March 2026 regarding a postal ballot being conducted exclusively through remote e-voting. The notices appeared in Financial Express (English)...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.